Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
57%
Ph phase_3
2
29%
Ph phase_4
1
14%

Phase Distribution

0

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Other(2)

Detailed Status

Completed5
unknown2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (57.1%)
Phase 32 (28.6%)
Phase 41 (14.3%)

Trials by Status

unknown229%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
unknownphase_2

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

NCT02776605
completedphase_2

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

NCT01660633
completedphase_4

Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)

NCT00504764
unknownphase_2

Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes

NCT01157403
completedphase_2

Risk-adapted Therapy for Adult Acute Myeloid Leukemia.

NCT01716793
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02776605Phase 2

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

Unknown
NCT01660633Phase 2

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Completed
NCT00504764Phase 4

Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)

Completed
NCT01157403Phase 2

Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes

Unknown
NCT01716793Phase 2

Risk-adapted Therapy for Adult Acute Myeloid Leukemia.

Completed
NCT00950768Phase 3

Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients

Completed
NCT00560053Phase 3

Pethema Multiple Myeloma 2000

Completed

All 7 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
7